TGF‐β–responsive CAR‐T cells promote anti‐tumor immune function

Molecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin

Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323 · see citing works

How regulatory T cells work

Vignali, D. A. A., Collison, L. W., & Workman, C. J. (2008) · Nature Reviews Immunology · doi:10.1038/nri2343 · Cited by 3,463 · see citing works

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · see citing works

Macrophage Cytokines: Involvement in Immunity and Infectious Diseases

Arango Duque, G., & Descoteaux, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00491 · Cited by 2,708 · see citing works

CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells

Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606 · see citing works

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112 · see citing works

Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis.

Yu, Q., & Stamenkovic, I. (2000) · PubMed · Cited by 1,952 · see citing works

Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis

Yu, Q., & Stamenkovic, I. (2000) · Genes & Development · doi:10.1101/gad.14.2.163 · Cited by 1,754 · see citing works

Immunosuppressive Strategies that are Mediated by Tumor Cells

Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,699 · see citing works

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C.-H., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,635 · see citing works

Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer

Siegel, P. M., & Massagué, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1208 · Cited by 1,600 · see citing works

Cell Contact–Dependent Immunosuppression by Cd4+Cd25+Regulatory T Cells Is Mediated by Cell Surface–Bound Transforming Growth Factor β

Nakamura, K., Kitani, A., & Strober, W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.5.629 · Cited by 1,596 · see citing works

The roles of TGFβ in the tumour microenvironment

Pickup, M. W., Novitskiy, S. V., & Moses, H. L. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3603 · Cited by 915 · see citing works

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2015) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 864 · see citing works

Regulatory T cells: how do they suppress immune responses?

Sakaguchi, S., Wing, K., Onishi, Y., Martín, P. P., & Yamaguchi, T. (2009) · International Immunology · doi:10.1093/intimm/dxp095 · Cited by 850 · see citing works

Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals <i>in vivo</i>

Chen, M.-L., Pittet, M. J., Gorelik, L., Flavell, R. A., Weissleder, R., von Boehmer, H., & Khazaie, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408197102 · Cited by 806 · see citing works

Roles of TGF-beta in hepatic fibrosis

Gressner, A. M. (2002) · Frontiers in bioscience · doi:10.2741/a812 · Cited by 785 · see citing works

T-helper-1-cell cytokines drive cancer into senescence

Braumüller, H., Wieder, T., Brenner, E., Aßmann, S., Hahn, M., Alkhaled, M., Schilbach, K., Essmann, F., Kneilling, M., Griessinger, C., et al. (2013) · Nature · doi:10.1038/nature11824 · Cited by 720 · see citing works

Increase of regulatory T cells in the peripheral blood of cancer patients.

Wolf, A. M., Wolf, D. G. F., Steurer, M., Gastl, G., Gunsilius, E., & Grubeck-Loebenstein, B. (2003) · PubMed · Cited by 655 · see citing works

Targeting the TGFβ pathway for cancer therapy

Neuzillet, C., Tijeras‐Raballand, A., Cohen, R., Cros, J. F., Faivre, S. J., Raymond, É., & Gramont, A. D. E. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.001 · Cited by 610 · see citing works

T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells

Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C., & Chen, Y. Y. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0231 · Cited by 609 · see citing works

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

Wang, X., Chang, W.-C., Wong, C. W., Colcher, D. M., Sherman, M. A., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2011-02-337360 · Cited by 600 · see citing works

Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor

MacDonald, K. G., Hoeppli, R. E., Huang, Q. B., Gillies, J. K., Luciani, D. S., Orban, P. C., Broady, R. C., & Levings, M. K. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82771 · Cited by 488 · see citing works

Tumor Evasion of the Immune System by Converting CD4+CD25− T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-β

Liu, V. C., Wong, L. Y., Jang, T. L., Shah, A. H., Park, I. I., Yang, X. J., Zhang, Q., Lonning, S. M., Teicher, B. A., & Lee, C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2883 · Cited by 453 · see citing works

Adoptively transferred effector cells derived from naïve rather than central memory CD8+ T cells mediate superior antitumor immunity

Hinrichs, C., Borman, Z. A., Cassard, L., Gattinoni, L., Spolski, R., Yu, Z.-Y., Sanchez-Perez, L., Muranski, P., Kern, S., Logun, C., et al. (2009) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0907448106 · Cited by 407 · see citing works

CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery

Fransson, M., Piras, E., Burman, J., Nilsson, B., Essand, M., Lu, B., Harris, R. A., Magnusson, P. U., Brittebo, E., & Loskog, A. S. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-112 · Cited by 372 · see citing works

Adapting a transforming growth factor β–related tumor protection strategy to enhance antitumor immunity

Bollard, C. M., Rössig, C., Calonge, M. J., Huls, M. H., Wagner, H.-J., Massagué, J., Brenner, M. K., Heslop, H. E., & Rooney, C. M. (2002) · Blood · doi:10.1182/blood.v99.9.3179 · Cited by 316 · see citing works

Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice

Klebanoff, C. A., Gattinoni, L., Palmer, D. C., Muranski, P. J., Ji, Y., Hinrichs, C. S., Borman, Z. A., Kerkar, S. P., Scott, C. D., Finkelstein, S. E., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0503 · Cited by 288 · see citing works

Rewiring T-cell responses to soluble factors with chimeric antigen receptors

Chang, Z. L., Lorenzini, M. H., Chen, X., Tran, U., Bangayan, N. J., & Chen, Y. Y. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2565 · Cited by 259 · see citing works

Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen-Specific Regulatory T Cells

Blat, D., Zigmond, E., Alteber, Z., Waks, T., & Eshhar, Z. (2014) · Molecular Therapy · doi:10.1038/mt.2014.41 · Cited by 246 · see citing works

Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-β Receptor

Foster, A. E., Dotti, G., Lu, A., Khalil, M., Brenner, M. K., Heslop, H. E., Rooney, C. M., & Bollard, C. M. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318177092b · Cited by 210 · see citing works

In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation

Earle, K., Tang, Q., Zhou, X., Liu, W., Zhu, S., Bonyhadi, M. L., & Bluestone, J. A. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.02.017 · Cited by 183 · see citing works

Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma

Bollard, C. M., Tripic, T., Cruz, C. R., Dotti, G., Gottschalk, S., Torrano, V., Dakhova, O., Carrum, G., Ramos, C. A., Liu, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.3179 · Cited by 181 · see citing works

TGF-β1 Uses Distinct Mechanisms to Inhibit IFN-γ Expression in CD4+ T Cells at Priming and at Recall: Differential Involvement of Stat4 and T-bet

Lin, J. T., Martin, S. L., Xia, L., & Gorham, J. D. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.5950 · Cited by 163 · see citing works

FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII

Yoon, J., Schmidt, A., Zhang, A.-H., Königs, C., Kim, Y. C., & Scott, D. W. (2017) · Blood · doi:10.1182/blood-2016-07-727834 · Cited by 150 · see citing works

Adoptive Transfer of Tumor-Reactive Transforming Growth Factor-β–Insensitive CD8+ T Cells: Eradication of Autologous Mouse Prostate Cancer

Zhang, Q., Yang, X. J., Pins, M., Javonovic, B., Kuzel, T. M., Kim, S., Parijs, L. V., Greenberg, N. M., Liu, V., Guo, Y., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3169 · Cited by 146 · see citing works

CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond

Chang, Z., & Chen, Y. Y. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.002 · Cited by 104 · see citing works

Immunotherapy of autoimmune encephalomyelitis with redirected CD4+CD25+ T lymphocytes

Mekala, D. J., & Geiger, T. L. (2004) · Blood · doi:10.1182/blood-2004-09-3579 · Cited by 103 · see citing works

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy

Zhang, L., Yu, Z., Muranski, P. J., Palmer, D. C., Restifo, N. P., Rosenberg, S. A., & Morgan, R. (2012) · Gene Therapy · doi:10.1038/gt.2012.75 · Cited by 93 · see citing works

Naturally Arising CD25+CD4+ Regulatory T Cells in Tumor Immunity

Nomura, T., & Sakaguchi, S. (2005) · Springer eBooks · doi:10.1007/3-540-27702-1_13 · Cited by 92 · see citing works

Quantification of active and total transforming growth factor-β levels in serum and solid organ tissues by bioassay

Khan, S. A., Joyce, J., & Tsuda, T. (2012) · BMC Research Notes · doi:10.1186/1756-0500-5-636 · Cited by 87 · see citing works

Interferon-γ and Tumor Necrosis Factor-α Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype

Jin, P., Zhao, Y., Liu, H., Chen, J., Ren, J., Jin, J., Bedognetti, D., Liu, S., Wang, E., Marincola, F. M., et al. (2016) · Scientific Reports · doi:10.1038/srep26345 · Cited by 84 · see citing works

Transforming Growth Factor Beta 1 is Significantly Elevated in Plasma of Patients Suffering from Renal Cell Carcinoma

Junker, U., Knöfel, B., Nuske, K., Rebstock, K., Steiner, T., Wunderlich, H., Junker, K., & Reinhold, D. (1996) · Cytokine · doi:10.1006/cyto.1996.0105 · Cited by 77 · see citing works

Redirecting human CD4+CD25+ regulatory T cells from the peripheral blood with pre-defined target specificity

Hombach, A. A., Kofler, D. M., Rappl, G., & Abken, H. (2009) · Gene Therapy · doi:10.1038/gt.2009.75 · Cited by 69 · see citing works

Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer.

Tokuno, K., Hazama, S., Yoshino, S., Yoshida, S., & Oka, M. (2009) · PubMed · Cited by 44 · see citing works

Immunotherapy for Human Renal Cell Carcinoma by Adoptive Transfer of Autologous Transforming Growth Factor β–Insensitive CD8+ T Cells

Wang, L., Wen, W., Yuan, J., Helfand, B. T., Yu, L., Shi, C., Tian, F., Zheng, J., Wang, F., Chen, L. V., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1758 · Cited by 43 · see citing works

Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function

Nguyen, P., Moisini, I., & Geiger, T. L. (2003) · Blood · doi:10.1182/blood-2003-04-1255 · Cited by 36 · see citing works

T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy

Quatromoni, J. G., Wang, Y., Vo, D. D., Morris, L. F., Jazirehi, A. R., McBride, W. H., Chatila, T. A., Koya, R. C., & Economou, J. S. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-127 · Cited by 31 · see citing works

Lung cancer immunotherapy: progress, pitfalls, and promises

Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01740-y · Cited by 1,102 · see citing works

TGFβ biology in cancer progression and immunotherapy

Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · see citing works

Engineering CAR-T Cells for Next-Generation Cancer Therapy

Hong, M., Clubb, J. D., & Chen, Y. Y. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.005 · Cited by 644 · see citing works

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Makni‐Maalej, K., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M. A., Maccalli, C., Cherif, H., Shahab Uddin, M. S., Steinhoff, M. S., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 638 · see citing works

Navigating CAR-T cells through the solid-tumour microenvironment

Hou, A. J., Chen, L. C., & Chen, Y. Y. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00189-2 · Cited by 556 · see citing works

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion

Gumber, D., & Wang, L. D. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103941 · Cited by 409 · see citing works

Overcoming TGFβ-mediated immune evasion in cancer

Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00413-6 · Cited by 377 · see citing works

The Natural Cytotoxicity Receptors in Health and Disease

Barrow, A. D., Martin, C. J., & Colonna, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00909 · Cited by 370 · see citing works

FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets

Saleh, R., & Elkord, E. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.022 · Cited by 355 · see citing works

CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities

Fonkoua, L. A. K., Sirpilla, O. L., Sakemura, R. L., Siegler, E. L., & Kenderian, S. S. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.03.009 · Cited by 299 · see citing works

Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma

Wang, D., Starr, R., Chang, W.-C., Aguilar, B., Alizadeh, D., Wright, S. L., Yang, X., Brito, A., Sarkissian, A., Ostberg, J. R., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2672 · Cited by 215 · see citing works

CAR T cells for brain tumors: Lessons learned and road ahead

Akhavan, D., Alizadeh, D., Wang, D., Weist, M. R., Shepphird, J. K., & Brown, C. E. (2019) · Immunological Reviews · doi:10.1111/imr.12773 · Cited by 211 · see citing works

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

Sorkhabi, A. D., Khosroshahi, L. M., Sarkesh, A., Mardi, A., Aghebati‐Maleki, A., Maleki, L. A., & Baradaran, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113882 · Cited by 215 · see citing works

Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy

Liu, Z., Zhou, Z., Dang, Q., Xu, H. M., Lv, J., Li, H., & Han, X. (2022) · Theranostics · doi:10.7150/thno.76854 · Cited by 198 · see citing works

Adoptive cell therapy for cancer treatment

Du, S., Yan, J., Xue, Y., Zhong, Y., & Dong, Y. (2023) · Exploration · doi:10.1002/exp.20210058 · Cited by 114 · see citing works

Current state and next-generation CAR-T cells in multiple myeloma

Manier, S., Ingegnere, T., Escure, G., Prodhomme, C., Nudel, M., Mitra, S., & Facon, T. T. F. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100929 · Cited by 112 · see citing works

Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank

Chuntova, P., Chow, F. E., Watchmaker, P. B., Galvez, M., Heimberger, A. B., Newell, E. W., Diaz, A. A., DePinho, R. A., Li, M. O., Wherry, E. J., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa277 · Cited by 89 · see citing works

The Role of TGF-β in Bone Metastases

Trivedi, T., Pagnotti, G. M., Guise, T. A., & Mohammad, K. S. (2021) · Biomolecules · doi:10.3390/biom11111643 · Cited by 91 · see citing works

Target selection of CAR T cell therapy in accordance with the TME for solid tumors.

Liu, B., Yan, L., & Zhou, M. (2019) · Europe PMC (PubMed Central) · Cited by 78 · see citing works

Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma

Li, N., Rodriguez, J. L., Yin, Y., Logun, M. T., Zhang, L., Yu, S., Hicks, K., Zhang, J. V., Zhang, L., Xie, C., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.020 · Cited by 74 · see citing works

Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors

Khan, S. H., Choi, Y., Veena, M. S., Lee, J. K., & Shin, D. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1489827 · Cited by 79 · see citing works

Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment

Andrea, A. E., Chiron, A., Mallah, S., Bessoles, S., Sarrabayrouse, G., & Hacein‐Bey‐Abina, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830292 · Cited by 75 · see citing works

IL-13Rα2/TGF- β bispecific CAR-T cells counter TGF- β -mediated immune suppression and potentiate anti-tumor responses in glioblastoma

Hou, A. J., Shih, R. M., Uy, B. R., Shafer, A. M., Chang, Z. L., Comin-Anduix, B., Güemes, M., Galić, Z., Phyu, S. M., Okada, H., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae126 · Cited by 77 · see citing works

Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors

Jung, I.-Y., Noguera-Ortega, E., Bartoszek, R. L., Collins, S. M., Williams, E. F., Suhoski, M. M., Jadlowsky, J. K., Plesa, G., Siegel, D. L., Chew, A., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101053 · Cited by 72 · see citing works

TGF-β and Cancer Immunotherapy

Maruyama, T., Chen, W., & Shibata, H. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00966 · Cited by 68 · see citing works

Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models

Si, X., Xiao, L., Brown, C. E., & Wang, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063154 · Cited by 69 · see citing works

Engineering chimeric antigen receptor T cells for solid tumour therapy

Liu, L., Qu, Y., Cheng, L., Yoon, C. W., He, P., Monther, A., Guo, T., Chittle, S. J., & Wang, Y. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1141 · Cited by 59 · see citing works

Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond

Zhou, Z., Wang, J., Wang, J., Yang, S., Wang, R., Zhang, G., Li, Z., Shi, R., Wang, Z., & Lu, Q. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02047-2 · Cited by 62 · see citing works

Molecular Engineering of the TGF-β Signaling Pathway

Zi, Z. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.05.022 · Cited by 54 · see citing works

CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro

Alishah, K., Birtel, M., Masoumi, E., Jafarzadeh, L., Mirzaei, H. R., Hadjati, J., Voss, R.-H., Diken, M., & Asad, S. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03146-0 · Cited by 50 · see citing works

Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma

Guo, J., & Tang, Q. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-00259-4 · Cited by 48 · see citing works

CAR T cells: engineered immune cells to treat brain cancers and beyond

Huang, Z., Dewanjee, S., Chakraborty, P., Jha, N. K., Dey, A., Gangopadhyay, M., Chen, X.-Y., Wang, J., & Jha, S. K. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01712-8 · Cited by 45 · see citing works

Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism

Gao, T. A., & Chen, Y. Y. (2022) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-092120-092914 · Cited by 41 · see citing works

Challenges and strategies associated with CAR-T cell therapy in blood malignancies

Liu, Z., Lei, W., Wang, H., Liu, X., & Fu, R. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00490-x · Cited by 43 · see citing works

A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives

Montoya, M., Gallus, M., Phyu, S. M., Haegelin, J., de Groot, J., & Okada, H. (2024) · Cells · doi:10.3390/cells13090726 · Cited by 40 · see citing works

CAR‐T‐cell products in solid tumors: Progress, challenges, and strategies

Qian, K., Li, G., Zhang, S., Fu, W., Li, T., Zhao, J., Lei, C., Wang, Y., & Hu, S. (2024) · Interdisciplinary medicine · doi:10.1002/inmd.20230047 · Cited by 34 · see citing works

Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors

Laurent, P.-A., Morel, D., Meziani, L., Depil, S., & Deutsch, É. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2158013 · Cited by 34 · see citing works

New advances in cancer therapy targeting TGF-β signaling pathways

Shou, M., Zhou, H., & Ma, L. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.100755 · Cited by 32 · see citing works

CAR T Cell Therapy Progress and Challenges for Solid Tumors

Stern, L. A., Jönsson, V. D., & Priceman, S. J. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_11 · Cited by 32 · see citing works

Therapeutic Implications of TGFβ in Cancer Treatment: A Systematic Review

Gómez‐Gil, V. (2021) · Cancers · doi:10.3390/cancers13030379 · Cited by 32 · see citing works

Targeting TGF-β signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction

Rana, P. S., Soler, D. C., Kort, J., & Driscoll, J. J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1059715 · Cited by 34 · see citing works

Chimeric antigen receptors designed to overcome transforming growth factor‐β‐mediated repression in the adoptive T‐cell therapy of solid tumors

Hartley, J., & Abken, H. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1064 · Cited by 30 · see citing works

Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics

Guerra, E., Pietro, R. D., Basile, M., Trerotola, M., & Alberti, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010405 · Cited by 30 · see citing works

Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy

Naeem, M., Hazafa, A., Bano, N., Ali, R., Farooq, M., Razak, S. I. A., Lee, T. Y., & Devaraj, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121409 · Cited by 31 · see citing works

Exploring the potential of TGFβ as a diagnostic marker and therapeutic target against cancer

Garg, P. K., Pareek, S., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116646 · Cited by 31 · see citing works

Coengineering specificity, safety, and function into T cells for cancer immunotherapy

Attianese, G. M. P. G., Ash, S., & Irving, M. B. (2023) · Immunological Reviews · doi:10.1111/imr.13252 · Cited by 29 · see citing works

CAR-engineered cell therapies: current understandings and future perspectives

Bayat, M., & Nahand, J. S. (2026) · Molecular Biomedicine · doi:10.1186/s43556-025-00401-4 · Cited by 31 · see citing works

TGFβ: Signaling Blockade for Cancer Immunotherapy

Chen, S., Mamaï, O., & Akhurst, R. J. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070620-103554 · Cited by 28 · see citing works

Functional Diversities of Regulatory T Cells in the Context of Cancer Immunotherapy

Gao, R., Shi, G., & Wang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.833667 · Cited by 28 · see citing works

Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors

Abken, H. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.165 · Cited by 26 · see citing works

Engineering primary T cells with chimeric antigen receptors for rewired responses to soluble ligands

Chang, Z., Hou, A. J., & Chen, Y. Y. (2020) · Nature Protocols · doi:10.1038/s41596-020-0294-8 · Cited by 25 · see citing works

Novel Cellular Therapies for Hepatocellular Carcinoma

Roddy, H., Meyer, T., & Roddie, C. (2022) · Cancers · doi:10.3390/cancers14030504 · Cited by 25 · see citing works

Innovative strategies to advance CAR T cell therapy for solid tumors.

Huang, M., Jinniu, D., Gao, L., & Zhou, J. (2020) · PubMed Central · Cited by 24 · see citing works

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Boccalatte, F. E., Mina, R., Aroldi, A., Leone, S., Suryadevara, C. M., Placantonakis, D. G., & Bruno, B. (2022) · Cancers · doi:10.3390/cancers14205108 · Cited by 23 · see citing works

Acute Myeloid Leukemia: Is It T Time?

Khoud, M. B., Ingegnere, T., Quesnel, B., Mitra, S., & Brinster, C. (2021) · Cancers · doi:10.3390/cancers13102385 · Cited by 22 · see citing works

Effect of phosphoric acid etching and self-etching primer application methods on dentinal shear bond strength.

Gökçe, K., Aykor, A., Ersoy, M., Özel, E., & Soyman, M. (2008) · PubMed · Cited by 19 · see citing works

How Can We Engineer CAR T Cells to Overcome Resistance?

Glover, M., Avraamides, S., & Maher, J. F. (2021) · Biologics · doi:10.2147/btt.s252568 · Cited by 19 · see citing works

Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors

Spiga, M., Martini, E., Maffia, M. C., Ciceri, F., Ruggiero, E., Potenza, A., & Bonini, C. (2024) · Seminars in Immunopathology · doi:10.1007/s00281-024-01011-y · Cited by 15 · see citing works

Probiotic-guided CAR-T cells for universal solid tumor targetingPreprint

Vincent, R. L., Gurbatri, C. R., Redenti, A., Coker, C., Arpaia, N., & Danino, T. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.10.463366 · Cited by 13 · see citing works

CAR-T cell therapy: Advances in digestive system malignant tumors

Xu, N., Wu, Z., Pan, J., Xu, X. L., & Wei, Q. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200872 · Cited by 12 · see citing works

Mathematical Modeling of Tumor and Cancer Stem Cells Treated with CAR-T Therapy and Inhibition of TGF-$$\beta $$

Swanson, E. R., Köse, E., Zollinger, E. A., & Elliott, S. (2022) · Bulletin of Mathematical Biology · doi:10.1007/s11538-022-01015-5 · Cited by 11 · see citing works

Capturing species‐wide diversity of the gut microbiota and its relationship with genomic variation in the critically endangered kākāpō

West, A. G., Digby, A., Santure, A. W., Guhlin, J. G., Dearden, P. K., Kākāpō Recovery Team, Taylor, M. W., & Urban, L. (2023) · Molecular Ecology · doi:10.1111/mec.16999 · Cited by 11 · see citing works

CAR-T cell technologies that interact with the tumour microenvironment in solid tumours

Taylor, C. A., Glover, M., & Maher, J. F. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2380894 · Cited by 12 · see citing works

Flagellin engineering enhances CAR-T cell function by reshaping tumor microenvironment in solid tumors

Niu, X., Zhang, P., Dai, L., Peng, X., Liu, Z., Tang, Y., Zhang, G., & Wan, X. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010237 · Cited by 11 · see citing works

Adventures in the Classroom Creating Role-Playing Games Based on Traditional Stories for the High School Curriculum

Zalka, C. V. (2012) · Digital Commons - East Tennessee State University (East Tennessee State University) · Cited by 11 · see citing works

Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell Therapies

Sherpally, D., & Manne, A. (2025) · Cancers · doi:10.3390/cancers17040589 · Cited by 13 · see citing works

Engineering Principles for Synthetic Biology Circuits in Cancer Immunotherapy

Shih, R. M., & Chen, Y. Y. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0769 · Cited by 10 · see citing works

Transforming growth factor-β micro-environment mediated immune cell functions in cervical cancer

Gnanagurusamy, J., Krishnamoorthy, S., & Muthusami, S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112837 · Cited by 9 · see citing works

Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies

Zhu, I., Piraner, D. I., & Roybal, K. T. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0962 · Cited by 9 · see citing works

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Ren, P., Zhang, C., Li, W., Wang, X., Liang, A., Yang, G., Xu, H., & Ma, P. (2022) · Advanced Biology · doi:10.1002/adbi.202101262 · Cited by 9 · see citing works

The soldiers needed to be awakened: Tumor-infiltrating immune cells

Yaping, W., Wang, Z., Zhuling, C., Li, R., Pengyu, F., Lili, G., Cheng, J., Bo, Z., Liu, L., Guangdong, H., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.988703 · Cited by 9 · see citing works

Exploring the potential of the convergence between extracellular vesicles and CAR technology as a novel immunotherapy approach

Bar, O., Porgador, A., & Cooks, T. (2024) · Journal of Extracellular Biology · doi:10.1002/jex2.70011 · Cited by 8 · see citing works

Myofibroblasts persist through immune privilege mechanisms to mediate oral submucous fibrosis: Uncovering the pathogenesis

Sharma, M., Shetty, S. S., Soi, S., & Radhakrishnan, R. A. (2024) · Journal of Oral Biology and Craniofacial Research · doi:10.1016/j.jobcr.2024.10.008 · Cited by 8 · see citing works

Multifaceted Role of the Transforming Growth Factor β on Effector T Cells and the Implication for CAR-T Cell Therapy

de Folmont, A. D. T., Bourhis, J.-H., Chouaı̈b, S., & Terry, S. (2021) · Immuno · doi:10.3390/immuno1030010 · Cited by 8 · see citing works

The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evidence

Barzegari, A., Salemi, F., Kamyab, A., Aratikatla, A., Nejati, N., Valizade, M., Eltouny, E., & Ebrahimi, A. (2024) · Journal of bone oncology · doi:10.1016/j.jbo.2024.100635 · Cited by 8 · see citing works

Outsmarting and outmuscling cancer cells with synthetic and systems immunology

Chen, L. C., & Chen, Y. Y. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.01.016 · Cited by 8 · see citing works

Recent advancements in improving the efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy for hepatocellular carcinoma

Ren, T., & Huang, Y. B. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03443-7 · Cited by 8 · see citing works

Overcoming resistance to anti‐CD19 CAR T‐cell therapy in B‐cell malignancies

Yang, X., Wei, J., & Zhou, J. (2022) · Hematological Oncology · doi:10.1002/hon.3036 · Cited by 7 · see citing works

The development of CAR T cells for patients with CNS malignancies

Binder, Z. A., Bagley, S. J., Foster, J., & O’Rourke, D. M. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01102-1 · Cited by 5 · see citing works

Photonanozyme–Kras–ribosome combination treatment of non-small cell lung cancer after COVID-19

Si, Q., Bai, M., Wang, X., Wang, T., & Qin, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1420463 · Cited by 5 · see citing works

Targeting the immune-privileged myofibroblast in oral submucous fibrosis by CAR T-cell therapy

Sarode, S. C., Sharma, N. K., Sarode, G. S., Sharma, M., & Radhakrishnan, R. A. (2022) · Medical Hypotheses · doi:10.1016/j.mehy.2022.110897 · Cited by 5 · see citing works

Toward the clinical development of synthetic immunity to cancer

Garcia, J. M., Burnett, C. E., & Roybal, K. T. (2023) · Immunological Reviews · doi:10.1111/imr.13245 · Cited by 7 · see citing works

Novel approaches to promote CAR T-cell function in solid tumors

Hull, C., & Maher, J. F. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1614164 · Cited by 5 · see citing works

Research progress on resistance mechanisms to CAR-T cell therapy in diffuse large B-cell lymphoma

Zhang, S., Liu, J., & Li, Z. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1696105 · Cited by 5 · see citing works

Decoding signaling architectures: CAR versus TCR dynamics in solid tumor immunotherapy

Chen, Z., & Zhou, X. (2025) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2025190 · Cited by 4 · see citing works

Harnessing cytokines to optimize chimeric antigen receptor-T cell therapy for gastric cancer: Current advances and innovative strategies

Cheng, Z., Cui, X., Li, S., Liang, Y., Yang, W., Ouyang, J., Wei, M., Yan, Z., & Yu, W. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117229 · Cited by 4 · see citing works

Application of Synthetic Antigen-Encoded Escherichia coli Nissle 1917 Probiotic-Guided PD-1/CD28 Receptor-Integrated CAR-T Cell Therapy as Targeted Therapy for Colorectal Cancer: A Literature Review

ARIAWAN, T. R., Divasta, I. G. M., BINTARI, A., de Liyis, B. G., & Wihandani, D. M. (2025) · Journal of Oncological Sciences · doi:10.37047/jos.galenos.2024.2024.104258 · Cited by 3 · see citing works

Cytokines and immune effector cell therapy

Haugh, A. M., & Frigault, M. J. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101628 · Cited by 3 · see citing works

Transforming Growth Factor‐Beta Signaling in Cancer: Therapeutic Implications, Challenges, and Pathways to Progress

Alabi, F. A., Okpalanwaka, I. F., Oyegbesan, A., Okoyeocha, E. O. M., Oladejo, M., & Imodoye, S. O. (2025) · MedComm – Oncology · doi:10.1002/mog2.70027 · Cited by 3 · see citing works

Cytokine-driven cancer immune evasion mechanisms

Arenas, E. J. (2025) · International review of cytology · doi:10.1016/bs.ircmb.2025.01.004 · Cited by 5 · see citing works

Therapeutic applications of engineered chimeric antigen receptors-T cell for cancer therapy

Hussain, A. (2022) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-022-00238-8 · Cited by 3 · see citing works

Next-generation immunotherapy biologics for glioblastoma

Schonfeld, E., Sjoholm, A., Ha, J. P. Y., Liu, J., Nageeb, G., Annagiri, S., Kim, L. H., Choi, J. H., & Lim, M. K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1775093 · Cited by 2 · see citing works

Chlorotoxin Redirects Chimeric Antigen Receptor T Cells for Specific and Effective Targeting of GlioblastomaPreprint

Wang, D., Starr, R., Chang, W.-C., Aguilar, B., Alizadeh, D., Wright, S. L., Yang, X., Brito, A., Sarkissian, A., Ostberg, J. R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.24.918888 · Cited by 2 · see citing works

New Emerging Biotherapies

Kayser, V., & Şen, M. (2020) · doi:10.1002/9781119564690.ch13 · Cited by 2 · see citing works

CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy

Billmeier, A., Khinvasara, K., Lang, F., Mohr, J., Reidenbach, D., Schork, M., Yildiz, I., & Diken, M. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2024416 · Cited by 1 · see citing works

CAR-T-Cell Therapy for Solid Tumors

Duggirala, S. (2025) · Springer eBooks · doi:10.1007/978-3-031-88695-9_6 · Cited by 1 · see citing works

CAR‐T cell therapy

Franklin, J., Pophali, P. A., Jackson, Z., Wald, D. N., & Avigan, D. (2024) · Wiley eBooks · doi:10.1002/9781394180486.ch25 · Cited by 1 · see citing works

Improving Chimeric Antigen Receptor (CAR) T cell therapy for solid tumours: Breaking down the suppressive barrier of the tumour microenvironment

Nijhof, S. (2019)

Programming Novel Cancer Therapeutics: Design Principles for Chimeric Antigen Receptors

Hou, A. J., & Chen, Y. Y. (2021) · Wiley eBooks · doi:10.1002/9783527815128.ch14

T-cell engineering strategies for tumors with low antigen density, and T-cell survival in the immunosuppressive tumor microenvironment of relapsed/refractory diffuse large B-cell lymphoma

Luan, R., & Deng, B. (2023) · Hematology and Oncology Discovery · doi:10.15212/hod-2022-0009

Engineering Robust T-Cell Response Against Immunosuppressive Tumors

Lorenzini, M. H. (2016) · eScholarship (California Digital Library)

Chimeric antigen receptors designed to overcome transforming growth factor‐β‐mediated repression in the adoptive T‐cell therapy of solid tumors

Hartley, J., & Abken, H. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1064 · Cited by 30 · see citing works

Enhancing TCR-T cell responses with a TGFβ-specific chimeric antigen receptorPreprint

Weist, M. R., BenDavid, E., Munguia, M. L., Reyes, J., Chen, X., Parisi, G., Cui, J., Foord, O., Chen, Y. Y., & Johnston, J. A. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7439311

Engineering chimeric antigen receptors to overcome the immunosuppressive solid tumor microenvironment

Hou, A. J. (2022) · eScholarship (California Digital Library)

442-I Enhancing TCR-T responses and overcoming the tumor microenvironment by combination with a TGFβ-specific CAR

Weist, M. R., BenDavid, E., Munguia, M. L., Reyes, J., Chen, X., Parisi, G., Cui, J., Foord, O., & Johnston, J. (2023) · doi:10.1136/jitc-2023-sitc2023.0442-i